Carlos Gaston Bisig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carlos Gaston Bisig has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Carlos A. Arce
Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), UNC-CONICET, Departamento de Química Biológica Ranwel Caputto, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, 5000 Córdoba, Argentina
3 shared publicationsYanina Ditamo
Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), UNC-CONICET, Departamento de Química Biológica Ranwel Caputto, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, 5000 Córdoba, Argentina
2 shared publicationsAgustina Zorgniotti
Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), UNC-CONICET, Departamento de Química Biológica Ranwel Caputto, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, 5000 Córdoba, Argentina
1 shared publicationAgustín Carbajal
Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC) UNC‐CONICET Departamento de Química Biológica Facultad de Ciencias Químicas Universidad Nacional de Córdoba Argentina
1 shared publicationCristian Hansen
LACE S.A., Córdoba, Argentina
1 shared publicationMaría E. Chesta
Centro de Investigaciones en Química Biológica de Córdoba (CIQUIBIC), UNC-CONICET, Departamento de Química Biológica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Argentina
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Elsevier in Neurobiology of Disease
- Vol. 147, 105164
Irreversible incorporation of L-dopa into the C-terminus of α-tubulin inhibits binding of molecular motor KIF5B to microtubules and alters mitochondrial traffic along the axon
- 1 January 2021
- Published by Elsevier in Neurobiology of Disease
- Vol. 147, 105164
Open AccessIrreversible incorporation of L-dopa into the C-terminus of α-tubulin inhibits binding of molecular motor KIF5B to microtubules and alters mitochondrial traffic along the axon
- Open Access
- 17 January 2018
- Published by Wiley in The FEBS Journal
- Vol. 285 (6) , 1064-1078
Post‐translational incorporation of 3,4‐dihydroxyphenylalanine into the C terminus of α‐tubulin in living cells
The C-terminal tyrosine (Tyr) of the α-tubulin chain is subjected to post-translational removal and readdition in a process termed the “detyrosination/tyrosination cycle”. We showed in previous studies using soluble rat brain extracts that l-3,4-dihydroxyphenylalanine (l-Dopa) is incorporated into the same site as Tyr. We now demonstrate that l-Dopa incorporation into tubulin also occurs in living cells. We detected such incorporation by determining the “tyrosination state” of tubulin before and after incubation of cells in the presence of l-Dopa. The presence of a tubulin isospecies following l-Dopa incubation that was not recognized by antibodies specific to Tyr- and deTyr-tubulin was presumed to reflect formation of Dopa-tubulin. l-Dopa was identified by HPLC as the C-terminal compound bound to α-tubulin. l-Dopa incorporation into tubulin was observed in Neuro 2A cells and several other cell lines, and was not due to de novo protein biosynthesis. Dopa-tubulin had microtubule-forming capability similar to that of Tyr- and deTyr-tubulin. l-Dopa incorporation into tubulin did not notably alter cell viability, morphology, or proliferation rate. CAD cells (a neuron-like cell line derived from mouse brain) are easily cultured under differentiating and nondifferentiating conditions, and can be treated with l-Dopa. Treatment of CAD cells with l-Dopa and consequent increase in l-Dopa-tubulin resulted in reduction of microtubule dynamics in neurite-like processes.
- 17 January 2018
- Published by Wiley in The FEBS Journal
- Vol. 285 (6) , 1064-1078
Open AccessPost‐translational incorporation of 3,4‐dihydroxyphenylalanine into the C terminus of α‐tubulin in living cells
The C-terminal tyrosine (Tyr) of the α-tubulin chain is subjected to post-translational removal and readdition in a process termed the “detyrosination/tyrosination cycle”. We showed in previous studies using soluble rat brain extracts that l-3,4-dihydroxyphenylalanine (l-Dopa) is incorporated into the same site as Tyr. We now demonstrate that l-Dopa incorporation into tubulin also occurs in living cells. We detected such incorporation by determining the “tyrosination state” of tubulin before and after incubation of cells in the presence of l-Dopa. The presence of a tubulin isospecies following l-Dopa incubation that was not recognized by antibodies specific to Tyr- and deTyr-tubulin was presumed to reflect formation of Dopa-tubulin. l-Dopa was identified by HPLC as the C-terminal compound bound to α-tubulin. l-Dopa incorporation into tubulin was observed in Neuro 2A cells and several other cell lines, and was not due to de novo protein biosynthesis. Dopa-tubulin had microtubule-forming capability similar to that of Tyr- and deTyr-tubulin. l-Dopa incorporation into tubulin did not notably alter cell viability, morphology, or proliferation rate. CAD cells (a neuron-like cell line derived from mouse brain) are easily cultured under differentiating and nondifferentiating conditions, and can be treated with l-Dopa. Treatment of CAD cells with l-Dopa and consequent increase in l-Dopa-tubulin resulted in reduction of microtubule dynamics in neurite-like processes.
- 6 September 2014
- Published by Wiley in The FEBS Journal
- Vol. 281 (21) , 4767-4778
Serum‐induced neurite retraction in CAD cells – involvement of an ATP‐actin retractile system and the lack of microtubule‐associated proteins
Cultured catecholamine‐differentiated cells [which lack the microtubule‐associated proteins (MAPs): MAP1B, MAP2, Tau, STOP, and Doublecortin] proliferate in the presence of fetal bovine serum, and, in its absence, cease dividing and generate processes similar to the neurites of normal neurons. The reintroduction of serum induces neurite retraction, and proliferation resumes. The neurite retraction process in catecholamine‐differentiated cells was partially characterized in this study. Microtubules in the cells were found to be in a highly dynamic state, and tubulin in the microtubules consisted primarily of the tyrosinated and deacetylated isotypes. Increased levels of acetylated or Δ2‐tubulin (which are normally absent) did not prevent serum‐induced neurite retraction. Treatment of differentiated cells with lysophosphatidic acid or adenosine deaminase induced neurite retraction. Inhibition of Rho‐associated protein kinase, ATP depletion and microfilament disruption each (individually) blocked serum‐induced neurite retraction, suggesting that an ATP‐dependent actomyosin system underlies the mechanism of neurite retraction. Nocodazole treatment induced neurite retraction, but this effect was blocked by pretreatment with the microtubule‐stabilizing drug paclitaxel (Taxol). Paclitaxel did not prevent serum‐induced or lysophosphatidic acid‐induced retraction, suggesting that integrity of microtubules (despite their dynamic state) is necessary to maintain neurite elongation, and that paclitaxel‐induced stabilization alone is not sufficient to resist the retraction force induced by serum. Transfection with green fluorescent protein–Tau conferred resistance to retraction caused by serum. We hypothesize that, in normal neurons (cultured or in vivo), MAPs are necessary not only to stabilize microtubules, but also to establish interactions with other cytoskeletal or membrane components to form a stable structure capable of resisting the retraction force.
- 6 September 2014
- Published by Wiley in The FEBS Journal
- Vol. 281 (21) , 4767-4778
Serum‐induced neurite retraction in CAD cells – involvement of an ATP‐actin retractile system and the lack of microtubule‐associated proteins
Cultured catecholamine‐differentiated cells [which lack the microtubule‐associated proteins (MAPs): MAP1B, MAP2, Tau, STOP, and Doublecortin] proliferate in the presence of fetal bovine serum, and, in its absence, cease dividing and generate processes similar to the neurites of normal neurons. The reintroduction of serum induces neurite retraction, and proliferation resumes. The neurite retraction process in catecholamine‐differentiated cells was partially characterized in this study. Microtubules in the cells were found to be in a highly dynamic state, and tubulin in the microtubules consisted primarily of the tyrosinated and deacetylated isotypes. Increased levels of acetylated or Δ2‐tubulin (which are normally absent) did not prevent serum‐induced neurite retraction. Treatment of differentiated cells with lysophosphatidic acid or adenosine deaminase induced neurite retraction. Inhibition of Rho‐associated protein kinase, ATP depletion and microfilament disruption each (individually) blocked serum‐induced neurite retraction, suggesting that an ATP‐dependent actomyosin system underlies the mechanism of neurite retraction. Nocodazole treatment induced neurite retraction, but this effect was blocked by pretreatment with the microtubule‐stabilizing drug paclitaxel (Taxol). Paclitaxel did not prevent serum‐induced or lysophosphatidic acid‐induced retraction, suggesting that integrity of microtubules (despite their dynamic state) is necessary to maintain neurite elongation, and that paclitaxel‐induced stabilization alone is not sufficient to resist the retraction force induced by serum. Transfection with green fluorescent protein–Tau conferred resistance to retraction caused by serum. We hypothesize that, in normal neurons (cultured or in vivo), MAPs are necessary not only to stabilize microtubules, but also to establish interactions with other cytoskeletal or membrane components to form a stable structure capable of resisting the retraction force.